Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma ...

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Genmab A/S (Nasdaq: GMAB) today announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging ... Read More

Epcoritamab Improves Outcomes, HRQOL in Patients With Relapsed/Refractory Follicular Lymphoma

Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ... Read More

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

Epcoritamab plus chemoimmunotherapy achieved an 87% overall response rate in relapsed/refractory DLBCL patients, with 65% achieving complete response. The regimen offers a potential bridge to ASCT or ... Read More

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

We recently published 11 Best Cancer Stocks to Buy Right Now. Genmab A/S is placed ninth among the best cancer stocks. Genmab A/S (NASDAQ:GMAB), a Danish biotechnology leader, specializes in ... Read More

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with ...

Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be ... Read More